About the conference

On 22^nd of April in Warsaw there was an educational Seminar titled: „Innovations in tumors of men genitourinary system treatment – evaluation of access in Poland”.

The primary target of the Seminar was pointing out the barriers in Poland in access to medical  technologies used in men genitourinary system treatment and discussion about ways to improve this condition.

The event was dedicated as well to representatives of the Ministry of Health, the National Health Fund, the Health Technology Assessment Organization, insurance companies, local governments, central councils, media and representatives of patients organizations, brand organizations and academics.

We encourage you to find more information in lectures given during the Seminar:

Joanna Krzywkowska – Custom chemotherapy – How to make the best decision under the relevant legislation? Procedure of payer decision-making process based of the Lower Silesian Regional Branch of the National Health Fund.

Marcin Hetnał – Radiation therapy of tumors of the men urinary system – availability in Poland

Zbigniew Jabłonowski – Problems in diagnostics and treatment of men bladder cancer in Poland

Karolina Skóra – Limits of the QUALY and sense of utilitarian approach in assessing the technology used in the terminal stages

Krzysztof Łanda – Sense of value evaluation in relation to break-even in oncology

Paulina Kieszkowska-Knapik – Reimbursement Act – implications for patients with tumors of the genitourinary system

Michael Jachimowicz – Indications of registration, custom cancer therapy, and the criteria for inclusion in treatment/drug programs in Poland

Cezary Pruszko – Risk sharing agreements – the range of law possibilities, and the practice in oncology in Poland

Tadeusz Włodarczyk – Presentation on the Tadeusz Koszarowski Association of Men with Prostate Diseases “GLADIATOR”

Activity of the Watch Health Care Foundation; monitoring of management performance of guaranteed benefits basket in Poland

Discussion focused on opportunities to improve access to services used in the treatment of the men genitourinary cancers.